Epigenetics means inheritable changes in the expression of proteins and hence the function of a cell WITHOUT alterations in the genetic code.
Such changes may be induced by DNA methylation and by modifications on histone proteins. Histones are basic proteins that are associated with DNA and their complex is termed chromatin. Enzymatic modifications in histones such as the reversible acetylation or methylation of the side chains of lysine residues contribute to gene regulation. They are involved in the pathogenesis of cancer but also other diseases and serve as a target for drug discovery. First inhibitors of epigenetic pathways have been approved for clinical use (e. g. histone deacetylases: Vorinostat (Zolinza). Non-histone proteins undergo similar modifications and epigenetic drugs may also exert effects via these signal transduction pathways.
Our main research focus is on assay development and the synthesis of inhibitors of histone-modifying enzymes. We focus on zinc-dependent histone deacetylases (HDACs), NAD+-dependent histone deacetylases (sirtuins), histone acetyltransferases (HATs) and histone methyltransferases as well as several diverse FAD- or Fe(II)/ketoglutrate-dependent histone demethylases. Part of the biological data is obtained in collaborating laboratories. In the area of molecular modeling, we collaborate with Prof. Dr. Wolfgang Sippl (University of Halle-Wittenberg).
Inhibitors of zinc-dependent histone deacetylases (HDACs)
- Synthesis of the first drug-like HDAC inhibitors
- Development of a small molecule HDAC substrate (MAL) and HTS HDAC assays
- Development of subtype-selective (HDAC1 und HDAC6) HDAC substrates
- Synthesis of HDAC6-selective inhibitors
- Biological activities: Inhibition of proliferation, induction of differentiation, radiosensitization of cancer cells, globin expression
Inhbitors of NAD+-dependent histone deacetylases (sirtuins)
- Synthesis of subtype-selective sirtuin inhibitors
- Development of a small molecule sirtuin substrate (ZMAL) and a HTS sirtuin assay
- Kinase inhibitors as new lead structures for sirtuin inhibitors (focused library screening)
- Biological activities: Inhibition of proliferation, block of HIV transcription
Inhibitors of histone acetyltransferases (HATs)
- Lead structure-based approach to new HAT inhibitors
- Biological activities: Inhibition of proliferation
Inhbitors of arginine methyltransferases (PRMTs)
- First inhibitors by a rational approach (virtual screening)
- First bisubstrate inhibitor of PRMTs
- Development of HTS assays for cellular arginine and lysine methylation
- Biological activities: Block of activation of hormone receptors
Selected references from our group
Chromatin modifications as targets for new anticancer drugs. (Review)
S. Schäfer, M. Jung;
Arch. Pharm. Chem. Life Sci. 338 (2005), 347-357.
Histone deacetylase inhibitors
Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation.
M. Jung G. Brosch, D. Kölle, H. Scherf, C. Gerhäuser, P. Loidl;
J. Med. Chem. 42 (1999), 4669-4679.
Induction of human gamma globin gene expression by histone deacetylase inhibitors.
H. Cao, G. Stamatoyannopoulos, M. Jung; Blood 103 (2004), 701-709.
Histone deacetylase substrates and assays
A Non-Isotopic Assay for Histone Deacetylase Activity.
K. Hoffmann, G. Brosch, P. Loidl, M. Jung; Nucleic Acids Res. 27 (1999), 2057-2058.
A homogeneous non-isotopic histone deacetylase activity assay.
B. Heltweg, M. Jung; J. Biomol. Screen. 8 (2003), 89-95.
Subtype selective substrates for histone deacetylases.
B. Heltweg, F. Dequiedt, B. L. Marshall, C. Brauch, M. Yoshida, N. Nishino, E. Verdin, M. Jung;
J. Med. Chem. 47 (2004), 5235-5243.
SIRT1 regulates HIV transcription via Tat deacetylation.
S. Pagans, A. Pedal, B. J. North, K. Kaehlcke, B. L. Marshall, A. Dorr, C. Hetzer-Egger, P. Henklein, R. Frye,
M. W. McBurney, H. Hruby, M. Jung, E. Verdin, M. Ott; PLoS Biology 3 (2005), e41.
Adenosine mimics as inhibitors of NAD+-dependent histone deacetylases - from kinase to sirtuin inhibitors.
J. Trapp, A. Jochum, R. Meier, L. Saunders, B. Marshall, E. Verdin, P. Goekjian, C. Kunick, W. Sippl, M. Jung;
J. Med. Chem. 49 (2006), 7307-7316.
Structure activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins).
J. Trapp, R. Meier, D. Hongwiset, M. U. Kassack,W. Sippl, M. Jung; ChemMedChem. 2 (2007), 1419-1431.
Characterization of novel inhibitors of histone acetyltransferases.
E. Eliseeva, V. Valkov, M. Jung, M. Jung; Mol. Cancer Ther. 6 (2007), 2391-2398.
Histon methyltransferase inhibitors
Target-based approach to inhibitors of histone arginine methyltransferases.
A. Spannhoff, R. Heinke, I. Bauer, P. Trojer, E. Metzger, R. Gust, R. Schüle, G. Brosch, W. Sippl, M. Jung,
J. Med. Chem. 50 (2007), 2319-2325.